Indian pharma firm Cipla receives USFDA approval to supply drugs from China facility in the second half of the fiscal year.

Cipla, an Indian pharma firm, plans to begin supplying drugs to the US market from its China facility in the second half of the fiscal year, following USFDA approval. The company is also working with USFDA to address compliance issues at its Indian plants. Cipla aims to expand into new therapeutic areas, invest in tech-based healthcare solutions, and develop a strong antimicrobial portfolio.